Indole-based CRTH2 antagonists

Abstract

Four patent applications from Oxagen, its first applications relating to chemical entities, claim either novel indolylacetic acids per se or the use of indolyl acetic acid derivatives as orphan receptor CRTH2 antagonists. Blockade of this receptor inhibits much of the pro-inflammatory effects of prostaglandin PGD₂ and is expected to provide a new method of treating allergic rhinitis and asthma.

Keywords::

• allergic rhinitis
• asthma
• COPD
• CRTH2
• DP receptor
• indole-3-acetic acid
• PGD₂